Genetic DAO Deficiency and Lower Urinary Tract Symptoms (NCT05676346) | Clinical Trial Compass
CompletedNot Applicable
Genetic DAO Deficiency and Lower Urinary Tract Symptoms
Spain100 participantsStarted 2022-10-11
Plain-language summary
The aim of this study is to determinate the prevalence os genetic DAO deficiency in patients with lower urinary tract symptoms.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* CACV socre \> 3 and/or
* IPSS score \> 7
Exclusion Criteria:
* Pharmacological treatment for LUTS in the 2 weeks prior to study inclusion (anticholinergics, antimuscarinics, or betamimetics).
* History of previous bladder and/or prostate surgery.
* History of bladder tumor in the previous 3 months.
* History of intravesical chemotherapy in the previous 3 months.
* Active urinary tract infection in the previous 2 weeks.
* Antihistamine treatment
* History of colorectal surgery and/or previous abdomino-perineal amputation.
What they're measuring
1
Genetic DAO deficiency prevalence
Timeframe: Baseline
Trial details
NCT IDNCT05676346
SponsorComplexo Hospitalario Universitario de A Coruña